BRIEF-Eylea (Aflibercept) Injection Demonstrates Positive Topline Results In Phase 3 Non-Proliferative Diabetic Retinopathy Trial

* EYLEA® (AFLIBERCEPT) INJECTION DEMONSTRATES POSITIVE TOPLINE RESULTS IN PHASE 3 NON-PROLIFERATIVE DIABETIC RETINOPATHY TRIAL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.